GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference September 4, 2025
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 August 11, 2025
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals May 19, 2025